Issues & Trends

EVERYBOT Inc. and WiseAI Jointly Develop AI Smart Senior Care Platform

Shin Ha-yeon
2026-07-23 13:47:45
[Edaily Reporter Shin Ha-yeon ] EVERYBOT Inc.(270660)announced on the 23rd that it has signed a Memorandum of Understanding (MOU) with WiseAI, a medical artificial intelligence (AI) platform company, to jointly develop and commercialize an AI-based smart senior care platform.

Under this agreement, the two companies plan to combine EVERYBOT Inc.’s AI-powered autonomous electric wheelchairs and autonomous robot technology with WiseAI’s medical-specific AI platform technology to jointly develop and commercialize smart care services for the elderly and people with limited mobility.
(Photo courtesy of EVERYBOT Inc.)

WiseAI is a medical AI platform company that offers the healthcare-specific AI solution “AURA/LAM,” the AI call and chatbot service “AiU,” and automated patient management solutions. These solutions have been adopted by numerous medical institutions, and the company also has experience executing government research and development (R&D) projects.

EVERYBOT Inc. is expanding its senior care business—including electric wheelchairs, care robots, and personal mobility devices—based on AI-powered autonomous driving technology. Through this collaboration, the company aims to develop service models that integrate AI, mobility, and digital healthcare technologies and strengthen its competitive edge in the smart senior care sector.

EVERYBOT Inc. stated, “Based on technologies to be developed in the future, we plan to expand our business into various sectors—including the senior care market, long-term care facilities, medical institutions, and public welfare—while also actively pursuing government R&D projects and entering global markets.”

Economy

Corporation

IT·Science

Economy

[Market In] Turning to Bank Loans Instead of Corporate Bonds… Will Even A-Rated Companies Turn Their Backs on the Bond Market Next Year?

The slump in the non-investment-grade corporate bond market—which has been centered on BBB-rated bonds this year—is expected to spread to A-rated companies next year. As the burden of issuing corporat…
2026-11-14 16:05:05

Corporation

Rookie Baropharm and Embattled Moalife Plus Face Paradoxical Volatility as GC Genome Anchors the Market [K-Bio Pulse]

Amid broader market volatility on Thursday, South Korea’s biopharmaceutical sector lacked a clear directional trend, leaving traditional, profitable pharmaceutical and biotech firms to anchor investor…
2026-11-14 12:47:03

IT·Science

“The Era of 1.5 Million Robots”… The Korean Company JP Morgan Has Singled Out

A forecast indicates that U.S. production of humanoid robots will reach up to 400,000 units by 2030 and 1.5 million units by 2035. Analysts predict that as the humanoid robot industry moves beyond tec…
2026-11-14 08:36:21